US 11,951,128 B2
Compositions and methods for the isolation and/or generation of specific CD4+ and CD8+ T-cell subsets
Hilde Cheroutre, La Jolla, CA (US); Nicolas Thiault, La Jolla, CA (US); Alexandre Larange, La Jolla, CA (US); and Hitoshi Iwaya, La Jolla, CA (US)
Assigned to LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, La Jolla, CA (US)
Appl. No. 16/635,015
Filed by LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, La Jolla, CA (US)
PCT Filed Aug. 2, 2018, PCT No. PCT/US2018/045072
§ 371(c)(1), (2) Date Jan. 29, 2020,
PCT Pub. No. WO2019/028295, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/540,501, filed on Aug. 2, 2017.
Claims priority of provisional application 62/540,498, filed on Aug. 2, 2017.
Prior Publication US 2021/0128614 A1, May 6, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 31/203 (2006.01); A61P 35/00 (2006.01); C07K 14/495 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/73 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 31/203 (2013.01); A61P 35/00 (2018.01); C07K 14/495 (2013.01); C07K 14/54 (2013.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01)] 8 Claims
 
1. A method of generating a population of tumor-specific CD4+ cytotoxic T-cells comprising contacting a population of tumor-specific CD4+ T-cells with an effective amount of a combination comprising cytokines and retinoic acid thereby generating tumor-specific CD4+ cytotoxic T-cells, and wherein the cytokines consist of TGF-β, and IL-27.